WP1. Project Management
The RareBoost Management Office will maintain the overall management of the project, guarantee its ongoing monitoring and the timely completion of the deliverables. (M01-72, WP leader: Dr. Gerhard Wingender)
WP2. Recruitment of the ERA Chair holder
IBG’s selection committee will oversee the open, transparent and merit-based selection of a leading scientist in rare disease research as RareBoost’s ERA Chair holder. The selection committee and the ERA Chair holder together will outline RareBoost’s working principles, including the research approach and projects, general managerial and administrative principles, the teaching & training and networking activities, outreach and stakeholder interactions, as well as the aspect of the commercialisation of project results. (M01-9, WP leader: Dr. Nese Atabey)
WP3. Research capacity building
The project’s main aim is to boost the quantity and quality of IBG’s rare disease research to achieve scientific excellence on an international level. Together with the ERA Chair holder and our stakeholders, we will define the areas in which IBG can make the biggest impact and implement tools to maximize synergies. A preliminary strategic research plan is outlined here. An essential tool to this end will be RareBoost’s teaching & training activities for IBG’s researchers and technical personnel together with IBG’s Teaching Center. (M07-72, WP leader: ERA Chair holder, TBD)
WP4. Soft skill capacity building
Besides strictly research related topics (WP3), teaching & training activities to strengthen the soft skills of all scientific, technical and administrative personnel at IBG are considered essential for RareBoost’s success. This will enhance the capacity and competitiveness of IBG’s personnel and foster their career development. (M07-72, WP leader: ERA Chair holder, TBD)
WP5. Smart specialization and innovation
To strengthen the innovative mind-set of our personnel and to facilitate the translation of RareBoost’s research findings into novel approaches for diagnostic and therapeutic interventions, we will closely collaborate with our regional, national and international private and public partners. This will be connected to a robust sustainability strategy to guarantee the long-term strategic growth and the economic sustainability of IBG’s rare disease efforts. (M07-72, WP leader: Dr. Mehmet Inan)
WP6. Networking, communication and dissemination to stakeholders
RareBoost’s ambitious goals cannot be achieved by IBG alone, but only together with many partners in the academic, private and public sector. Therefore, particular efforts will be made to establish, manage and maintain effective and beneficial mutual communication and interaction with all of our stakeholders. We invite everyone who wants to improve the lives of rare disease patients to reach out to us, so that we can find ways to combine and amplify our efforts. (M01-72, WP leader: Dr. Duygu Sag)